MRO Magazine

MEDICREA: 2015 Annual Sales

By Business Wire News   


Regulatory News:

The MEDICREA group (Paris:ALMED) (Alternext Paris: FR0004178572 – ALMED, PEA-PME eligible), which specializes in the development and manufacturing of innovative surgical technologies for the treatment of spinal pathologies, announces its 2015 annual sales.

€ millions     2014     2015     Δ
1st half

2nd half











Variations in foreign currency rates hada positive impact of 10% on 2015 annual sales.

2015 annual sales totaled 27.8 million euros, up +15% on the 2014 figure, with record billings of 14 million euros over the 2nd half of 2015.

We are beginning to reap the benefits of the commercial investments carried out in 2014 that led to the opening of new export markets in 2015, essentially in Eastern Europe and South America. This trend is likely to continue in 2016 thanks to the signing of new distribution agreements in Asia and the Middle East, the creation of our German subsidiary and the implementation of a new marketing organization in our British entity. We are making headway in France, where surgeons’ interest in our innovations and our UNiD™ customized implant platform enabled us to generate a 23% increase in sales compared with the previous year. We are continuing to invest heavily in our priority market in the United States, which accounted for 60% of total sales over the last year, in order to expand our sales force and directly promote our customized implants among patients”,comments Denys SOURNAC, Chairman and CEO of MEDICREA.

From January 11 to 15, 2016, the Group is participating in the JPMorgan Healthcare Conference in San Francisco, one of the world’s largest annual financial events in the healthcare sector that is attended by the main institutional investors, as well as by numerous American financial analysts. “With around thirty appointments, this conference is an excellent opportunity for MEDICREA to introduce to American financial players our development strategy and our innovative technologies, and in particular the UNiD™ osteosynthesis rods that are specifically customized for each patient, which were launched in 2015 in the United States and which strengthen our leadership position in personalized spine surgery”, adds Denys SOURNAC.

Next publication: 2015 annual results, on April 6, 2016 (after market)


The MEDICREA Group specializes in the design, manufacture, and distribution of innovative proprietary technologies devoted exclusively to spinal surgery. Operating in a $10 billion market, MEDICREA is a small to medium-sized business with 140 employees, including 40 at its MEDICREA USA Corp. subsidiary based in New York City.

The Company enjoys an excellent and ever-improving reputation, and develops unique scientific partnerships with some of the most visionary and creative spine surgeons in France, the UK, and the USA. The products developed and patented by MEDICREA provide neurosurgeons and orthopedic surgeons specializing in the spine with new and less-invasive surgical solutions that are faster and easier to implement than traditional techniques.

MEDICREA has also become a pioneer and global leader in the manufacturing of customized implants for personalized spinal surgery with the development of a comprehensive process incorporating the software analysis of each patient, the pre-surgical planning of the surgical strategy, and the production of customized spinal osteosynthesis rods (UNiD™ rod) and lumbar interbody osteosynthesis cages (UNiD™ ALIF cage) that are made to measure by a 3D printer.

The Group’s headquarters are based near Lyon, France. It also has an implant and surgical instrument manufacturing facility located in La Rochelle, France, as well as four distribution subsidiaries in the USA, the UK, France and Germany.

ISIN: FR 0004178572 – Ticker: ALMED

Denys Sournac, Founder, Chairman and CEO
Fabrice Kilfiger, Chief Financial Officer
Tel: +33 (0)4 72 01 87 87
Erich Sandoval for MEDICREA
Tel: +1 917-497-2867
Investor Relations & Strategic Communications
Tristan Roquet Montégon
Tel: +33 (0)1 44 71 00 16


Stories continue below

Print this page